Skip to main content

Rapid In Vivo Evaluation of Immuno-Modulatory Therapies Using Hu-PBMC NSG™ Mice

Published Date

Do you need a translationally relevant preclinical platform to rapidly assess or develop human T cell immunomodulatory therapies? Engrafting NSG mice with human peripheral blood mononuclear cells (Hu-PBMC) leads to xenogeneic activation and proliferation of human T cells. The resulting Hu-PBMC NSG models can then be used to test the efficacy of human T cell immunomodulatory therapeutics for graft-versus-host disease (GvHD), autoimmune disorders, and cancer.

During this webinar, we will discuss:

  • Data quantitating and characterizing the development and progression of GvHD
  • Phenotypic characterization of human T effector and memory cell populations
  • In vivo study data demonstrating modulation of human T cells using clinically relevant immunotherapeutics